Safety and cardiometabolic efficacy of novel antidiabetic drugs.
Liana MichaudMatthew SeploweJuliet MeirWilbert S Aronow
Published in: Expert opinion on drug safety (2023)
Future avenues of research to explore include the use of novel antidiabetic agents to reduce post-myocardial infarction (MI) CV risk and arrhythmias independent of their use as diabetic agents.